Ultragenyx Pharma (RARE) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Piper Jaffray Raises Price Target on Ultragenyx Pharma (RARE) to $82; Reiterates Overweight
August 9, 2016 8:53 AM EDTPiper Jaffray reiterated an Overweight rating on Ultragenyx Pharma (NASDAQ: RARE), and raised the price target to $82.00 (from $70.00), following the company's 2Q earnings report.
Analyst Steven Breazzano commented, "After the close, RARE reported 2Q earnings and provided an... More
